(P-574) Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies

Thursday, October 17, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

William R. Short, MD

Associate Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania, United States

Parul Patel, MSW

Director, Clinical Pharmacology
ViiV Healthcare
Durham, North Carolina, United States

GV

Gustavo Verdier, BSc, BPharm, MBA

ViiV Healthcare, Montréal, QC, Canada
Pointe-Claire, Quebec, Canada
AP

Ana Puga, MD, FAAP, AAHIVS

Regional Medical Director
ViiV Healthcare
RTP, North Carolina, United States
AW

Andrew Weber, MS

ViiV Healthcare
Durham, North Carolina, United States
LR

Leigh Ragone, MS

Strategy & Governance Director
ViiV Healthcare
RTP, North Carolina, United States
EF

Eva Fernvik, PhD

ViiV Healthcare
Stockholm, Sodermanlands Lan, Sweden
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States
VD

V. Paul DiMondi, PharmD (he/him/his)

Scientific Communications Director
ViiV Healthcare
Durham, North Carolina, United States
Clifford B. Jones, BSc MSc MB ChB (he/him/his)

Global medical lead
ViiV Healthcare, Brentford, UK
London, England, United Kingdom